Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM) :: NetworkMedica

pausar

ir hacia adelante

FDA Panel Rejects Avastin as Breast Cancer Drug |

Legals

Patent Challenge (ANDA)

Court Decisions

Blocks (Pharma)

Blocks (Biotecnology)

Pharma

Review Extension

Clinical Trials

Forecast (Investments Banks and Analysts)

Business News (Licences, Deals)

Mergers & Acquisitions

Biotechnology

Review Extension

Clinical Trials

Forecast (Investments Banks and Analysts)

Business News (Licences, Deals)

Mergers & Acquisitions

Generics

Tentative Approval

Industry

Express Rankings

PRNewswire

Network Médica

Suscribe
More Information

I wish to receive the free Newsletter

Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)

01-12-2008 | 15:58 hs.

|

See full article

Páginas: [1] - [2] - [3] - [4]

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452

SOURCE Cadence Pharmaceuticals, Inc.

See full article

Páginas: [1] - [2] - [3] - [4]

Estimated reading time: 9:26

Word count: 12588

Most read articles

NICE: Avastin rejected for the treatment of advanced breast cancer // 07/09/2010

BLOGS
NM Extra
VIDEOS